Table 2.
Patient demographics of 46 breast cancer patients attempting to conceive through intercourse or ART
| Characteristics | Overall (n = 46) | Intercourse (n = 34) | ART (n = 12) | p-value |
|---|---|---|---|---|
| Age at diagnosis (years), mean (SD1) (n = 45) | 33 (4.5) | 32.8 (3.9) | 34.6 (5.9) | 0.074 |
| Age at first conception attempt in years, mean (SD) (n = 45) | 37 (4.1) | 37.3 (3.6) | 39.2 (5.0) | 0.180 |
| Nulliparous | 28 (60.1) | 22 (64.7) | 6 (50.0) | 0.370 |
| Hormone receptor2 | ||||
| ER+ (n = 44) | 26 (59.1) | 22 (66.7) | 4 (36.4) | 0.077 |
| HER2+ (n = 43) | 12 (27.9) | 9 (28.1) | 3 (27.3) | 0.957 |
| ER-PR-HER2- (n = 44) | 15 (34.1) | 9 (27.3) | 6 (54.6) | 0.098 |
| BRCA3 positive (n = 45) | 6 (13.3) | 4 (12.1) | 2 (16.7) | 0.649 |
| Pre-chemo AFC4, median (IQR5) (n = 45) | 10 (5-15) | 11 (5-14) | 9 (7-19) | 0.740 |
| Cyclophosphamide use (n = 43) | 35 (81.4) | 27 (84.4) | 8 (72.7) | 0.392 |
| GnRH6 agonist use during chemotherapy (n = 44) | 23 (50.0) | 17 (50.0) | 6 (50.0) | 0.723 |
| Time between attempt and chemotherapy end (years), median (IQR) | 3.2 (2.1-5.1) | 3.2 (2.1-5.1) | 3.3 (2.3-5.0) | 0.143 |
| Length of attempt (months), median (IQR) (n = 44) | 3 (1-8) | 4 (2-9) | 1 (1-1) | < 0.001* |
| Number of pre-treatment eggs frozen per cycle, mean (range) (n = 12) | 16 (2-32) | 14 (2-23) | 21 (14-32) | 0.624 |
| Number of pre-treatment embryos frozen per cycle, mean (range) (n = 24) | 9 (1-21) | 8 (3-19) | 9 (1-21) | 0.174 |
Data are expressed as n (%) unless otherwise specified
Total n = 46 unless otherwise specified
1SD standard deviation
2ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
3BRCA breast cancer gene
4AFC antral follicle count
5IQR interquartile range
6GnRH gonadotropin-releasing hormone